The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Early treatment response monitoring in gastrointestinal cancers with ctDNA
Traditional tumor response assessments rely on radiographic scans after two months, often exposing patients to unnecessary toxicity before determining efficacy. Sakti Chakrabarti, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, offers circulating tumor DNA (ctDNA) testing as a faster alternative, allowing response evaluation within around 3 weeks. By measuring baseline ctDNA levels and tracking changes over time, clinicians can quickly identify whether treatment is effective. Using a test which provides quantifiable ctDNA levels, a strong correlation between early ctDNA decline and radiographic response was reported. While further validation is needed, this approach could spare patients from ineffective treatments and enable faster therapy adjustment to improve outcomes. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
